$GH

Saia John G. sold $1.3M of GH

Saia John G. (Chief Legal Officer) sold 10,000 shares of Guardant Health, Inc. (GH) at an average of $125.08 ($125.08–$126.08, $1.25M total) across 2 trades on 2026-05-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Saia John G.
Published May 28, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:45 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GH
Neutral
high confidence
Mentioned
$GH
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale details (shares, price range, total value) executed under a pre-arranged 10b5-1 plan.

02

Market read

This provides incremental transparency on insider selling, but it is not a fundamental catalyst by itself.

03

What to watch

The filing does not state motivations; traders should compare with prior insider activity frequency and whether sales cluster around specific events (earnings, trial readouts).

Relevance 5/10Novelty 3/10Timing: filed 2026-05-28, transaction dated 2026-05-27

Background

The article is an SEC Form 4 insider transaction disclosure for Guardant Health, Inc.

Company-level read

Ticker impact

$GHNeutralHigh confidence
Context

Guardant Health disclosed an insider Form 4 showing CFO John G. Saia sold about 10,000 shares in open-market trades under a 10b5-1 plan.

Expected impact

Likely minimal impact on the stock, unless investors extrapolate unusual selling beyond the plan.

Evidence & confidence

The filing specifies a Rule 10b5-1 pre-arranged plan and an open-market sale; the disclosed transaction is not tied to a new operational or regulatory event.

Market effects

No clear sector read-through; this is company-specific insider activity without new guidance or trial/regulatory updates.

None indicated.

None indicated.

Counterpoint

Insider sales can be interpreted as diversification rather than bearish information, especially when executed under a 10b5-1 plan.

Key entities

  • Guardant Health, Inc.

    Company whose insider transaction was disclosed on Form 4.

  • John G. Saia

    Chief Legal Officer who sold shares in open-market trades under a 10b5-1 plan.

Related articles

$GHHighAI 9/10

Guardant Health (GH) Q2 2026 Earnings Call Transcript

Guardant Health (GH) reported Q2 2026 revenue of $335 million, up 44% year over year, driven by Oncology, Biopharma & Data, and Screening. Oncology revenue was $219.1 million, up 38%, with test volumes around 104,000. Full-year guidance: revenue $1.34 to $1.36 billion and free cash flow burn $195 to $205 million.

$GHMedAI 8/10

New blood test to detect colon cancer clears FDA approval

The FDA approved Freenome’s SimpleScreen blood test for colorectal cancer screening in adults aged 45+ at average risk. In a study of 48,000+ people, it detected about 80% of colorectal cancers and correctly tested negative in about 90% without cancer or advanced precancer. It is expected to launch this fall with Abbott. Guardant Health’s Shield was approved in 2024.

$GHMedAI 8/10

Guardant Health, Inc. Q2 2026 Earnings Call Summary

Guardant Health reported 44% YoY Q2 2026 revenue growth, citing strong Oncology and Screening performance. It raised full-year 2026 revenue guidance to $1.34B-$1.36B and expects lower Shield cost per test. FDA approval of Guardant360 Liquid CDx and UnitedHealth coverage for Shield from Aug. 1, 2026 are key catalysts.

$GHHighAI 9/10

Why is Guardant Health stock surging today?

Nasdaq sees best day in over a month as Microsoft breathes life back into AI trade Investing.com -- Guardant Health stock surged 8.8% in after-hours trading after the Palo Alto-based liquid biopsy pioneer reported second-quarter 2026 results that significantly exceeded revenue expectations, with sales reaching $335 million — a 44% year-over-year increase that beat the Wall Street consensus of roughly $314 million by approximately 6.4%.